ALLO:NSD-Allogene Therapeutics, Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 37.26

Change

+0.24 (+0.65)%

Market Cap

USD 5.16B

Volume

0.52M

Average Target Price

USD 50.00 (+34.19%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is developing UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate, which is in Phase I clinical trials for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL; ALLO-501, an anti-CD19 allogeneic CAR T cell product candidate that is in Phase I clinical trial for the treatment of R/R non-Hodgkin lymphoma; and ALLO-501A for the treatment R/R large B-cell lymphoma or transformed follicular lymphoma. It is also developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-819, an allogeneic CAR T cell product candidates for the treatment of acute myeloid leukemia; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; and DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc., as well as clinical trial collaboration agreement with SpringWorks Therapeutics, Inc. Allogene Therapeutics, Inc. was founded in 2017 and is headquartered in South San Francisco, California.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-09-28 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX Vertex Pharmaceuticals Incorpo..

-0.45 (-0.17%)

USD69.85B 33.27 26.59
REGN Regeneron Pharmaceuticals, Inc

-2.14 (-0.37%)

USD61.08B 21.61 16.69
SGEN Seattle Genetics, Inc

+5.56 (+3.01%)

USD32.18B N/A N/A
MRNA Moderna, Inc

+1.08 (+1.55%)

USD27.41B N/A N/A
ALXN Alexion Pharmaceuticals, Inc

-1.13 (-0.99%)

USD25.08B 29.87 27.00
BGNE BeiGene, Ltd

-1.75 (-0.62%)

USD24.87B N/A N/A
RPRX Royalty Pharma plc

+1.14 (+2.85%)

USD24.33B 34.81 9.50
GMAB Genmab A/S

+0.93 (+2.58%)

USD23.71B 25.56 2.87
IMMU Immunomedics, Inc

+0.16 (+0.19%)

USD19.73B N/A N/A
INCY Incyte Corporation

+3.81 (+4.40%)

USD18.93B 47.64 35.20

ETFs Containing ALLO

Symbol Name Weight Mer Price(Change) Market Cap
T3KE:F HAN-GINS Tech Megatrend E.. 0.00 % 0.75 %

+0.24 (+2.50%)

USD0.02B
T3KE:XETRA HAN-GINS Tech Megatrend E.. 0.00 % 0.75 %

+0.20 (+2.10%)

USD0.02B

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 43.42% 77% C+ 84% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 43.42% 77% C+ 84% B
Trailing 12 Months  
Capital Gain 36.68% 61% D- 77% C+
Dividend Return N/A N/A N/A N/A N/A
Total Return 36.68% 61% D- 77% C+
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 6.28% N/A N/A 57% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 6.28% N/A N/A 52% F
Risk Return Profile  
Volatility (Standard Deviation) 22.32% N/A N/A 64% D
Risk Adjusted Return 28.12% N/A N/A 52% F
Market Capitalization 5.16B 94% A 89% B+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 4.16 47% F 30% F
Price / Cash Flow Ratio -37.54 89% B+ 92% A-
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -24.98% 85% B 34% F
Return on Invested Capital -29.51% 78% C+ 25% F
Return on Assets -15.08% 79% C+ 23% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 17.81 8% F 4% F
Short Percent 12.94% 21% F 17% F
Beta 1.44 54% F 32% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector